September 2018 | Meán Fómhair 2018

Resolution of Inflammation, Infection and Tissue Regeneration

Fri, 7 September 18 14:59

For centuries, physicians and scientists have thought of inflammation as the body's acute response to infection or injury, but in recent decades it's become clear that chronic inflammation drives pathologies as diverse as cancer, diabetes, and Alzheimer's disease. Controlling this aberrant inflammation, however, has proven difficult.

Conventional anti-inflammatory drugs work by antagonizing the body's pro-inflammatory hormones, but that approach also suppresses immunity, opening the patient to secondary infections. A newer strategy relies on recently discovered resolution mediators, compounds that the body makes naturally to resolve inflammatory responses without suppressing other parts of the immune system. Drugs targeting this process have shown immense potential to treat many of the world's most serious diseases, with fewer side effects than existing therapies.

Professor Catherine GodsonOn June 25–26, 2018, the New York Academy of Sciences hosted Resolution of Inflammation, Infection and Tissue Regeneration, a symposium featuring many of the top researchers in the rapidly developing field of resolution pharmacology. The meeting featured Professor Catherine Godson, UCD Professor of Molecular Medicine and Director, UCD Diabetes Complications Research Centre among the keynote speakers.  In two days of oral presentations, a poster session, and an extensive panel discussion, speakers and attendees reviewed the biggest advances and challenges in resolution biology. The meeting covered the basic biology of inflammation and its resolution, studies on animal models of chronic and acute diseases, and clinical trials of promising new inflammation-resolving drugs.

You can find out more about the meeting from the e-Briefing which has been published by the New York Academy of Sciences.



Report by Alan Dove, New York Academy of Sciences. Reproduced and adapted with permission.